abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
pharma · TTR-mediated Amyloidosis · Hypertension · ALNY
Alnylam Netherlands
Alnylam Netherlands B.V.
Alnylam Netherlands drug portfolio — 37 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Cambridge, USA HQ
2002 Founded
2,826 Employees
Public company Type
ALNY · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2002
- Employees
- 2,826
- Programs
- 84
- Drugs
- 37
- Patents
- 379
Alnylam Netherlands pipeline
Portfolio lens on 37 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Alnylam Netherlands drug portfolio — 37 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
Development asset linked to Alnylam Netherlands in public FDA and regional records.
-
Development asset linked to Alnylam Netherlands in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Alnylam Netherlands in public FDA and regional records.
-
Development asset linked to Alnylam Netherlands in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Alnylam Netherlands in public FDA and regional records.
-
colchicine
Musculo-skeletal system (M04)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Alnylam Netherlands in public FDA and regional records.
-
diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) and haemophilus influenzae type-b (hib) conjugate vaccine (adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Alnylam Netherlands's portfolio.
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
givosiran
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Alnylam Netherlands's portfolio. Molecular target: 5-aminolevulinate synthase mRNA.
- Target
- 5-aminolevulinate synthase mRNA
- Mechanism
- 5-aminolevulinate synthase mRNA RNAi inhibitor
-
US regulatory status: approved. Molecular target: 5-aminolevulinate synthase mRNA.
- Target
- 5-aminolevulinate synthase mRNA
- Mechanism
- 5-aminolevulinate synthase mRNA RNAi inhibitor
-
haemophilus b conjugate (meningococcal protein conjugate) and hepatitis b (recombinant) vaccine
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Alnylam Netherlands's portfolio. Molecular target: Surface antigen (HBsAg).
- Target
- Surface antigen (HBsAg)
- Mechanism
- Surface antigen (HBsAg) vaccine antigen
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.
- Target
- Solute carrier family 12 member 3
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
-
Development asset linked to Alnylam Netherlands in public FDA and regional records.
-
Development asset linked to Alnylam Netherlands in public FDA and regional records.
-
Development asset linked to Alnylam Netherlands in public FDA and regional records.
-
lumasiran
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Alnylam Netherlands's portfolio. Mechanism: Hydroxyacid oxidase 1 mRNA RNAi inhibitor.
- Mechanism
- Hydroxyacid oxidase 1 mRNA RNAi inhibitor
-
US regulatory status: approved. Molecular target: Hydroxyacid oxidase 1 mRNA.
- Target
- Hydroxyacid oxidase 1 mRNA
- Mechanism
- Hydroxyacid oxidase 1 mRNA RNAi inhibitor
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
patisiran
Nervous system (N07)Nervous system (N07) compound in Alnylam Netherlands's portfolio. Molecular target: Transthyretin mRNA.
- Target
- Transthyretin mRNA
- Mechanism
- Transthyretin mRNA RNAi inhibitor
-
US regulatory status: approved. Molecular target: Transthyretin mRNA.
- Target
- Transthyretin mRNA
- Mechanism
- Transthyretin mRNA RNAi inhibitor
-
Development asset linked to Alnylam Netherlands in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Complement C5.
- Target
- Complement C5
- Mechanism
- Complement C5 inhibitor
-
Development asset linked to Alnylam Netherlands in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Alnylam Netherlands in public FDA and regional records.
-
Development asset linked to Alnylam Netherlands in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Molecular target: Retinoic acid receptor.
- Target
- Retinoic acid receptor
- Mechanism
- Retinoic acid receptor agonist
-
vutrisiran
Nervous system (N07)Nervous system (N07) compound in Alnylam Netherlands's portfolio. Molecular target: Transthyretin mRNA.
- Target
- Transthyretin mRNA
- Mechanism
- Transthyretin mRNA rnai inhibitor
-
US regulatory status: approved. Molecular target: Transthyretin mRNA.
- Target
- Transthyretin mRNA
- Mechanism
- Transthyretin mRNA rnai inhibitor